Stroke: disappointing results for clazosentan in CONSCIOUS-2.
作者： Philip M. Meyers , E. Sander Connolly
DOI: 10.1038/NRNEUROL.2011.168
关键词:
摘要: Clazosentan—a drug previously demonstrated to reduce angiographic vasospasm in patients with aneurysmal subarachnoid hemorrhage—had no significant effect on vasospasm-related morbidity and mortality the CONSCIOUS-2 trial. A multifactorial cause for delayed ischemic neurological deficits might partly account these negative findings.
nature.com
sci-hub.se 参考文章(9)
Hartmut Vatter, Jürgen Konczalla, Volker Seifert, Endothelin related pathophysiology in cerebral vasospasm: what happens to the cerebral vessels? Acta Neurochirurgica. ,vol. 110, pp. 177- 180 ,(2011) , 10.1007/978-3-7091-0353-1_31
Sang-Bae Ko, H. Alex Choi, Amanda Mary Carpenter, Raimund Helbok, J. Michael Schmidt, Neeraj Badjatia, Jan Claassen, E. Sander Connolly, Stephan A. Mayer, Kiwon Lee, Quantitative Analysis of Hemorrhage Volume for Predicting Delayed Cerebral Ischemia After Subarachnoid Hemorrhage Stroke. ,vol. 42, pp. 669- 674 ,(2011) , 10.1161/STROKEAHA.110.600775
R. Webster Crowley, R. Medel, Aaron S. Dumont, Don Ilodigwe, Neal F. Kassell, Stephan A. Mayer, Daniel Ruefenacht, Peter Schmiedek, Stephan Weidauer, Alberto Pasqualin, R. Loch Macdonald, Angiographic Vasospasm Is Strongly Correlated With Cerebral Infarction After Subarachnoid Hemorrhage Stroke. ,vol. 42, pp. 919- 923 ,(2011) , 10.1161/STROKEAHA.110.597005
Lewis Z. Leng, Matthew E. Fink, Costantino Iadecola, Spreading Depolarization: A Possible New Culprit in the Delayed Cerebral Ischemia of Subarachnoid Hemorrhage JAMA Neurology. ,vol. 68, pp. 31- 36 ,(2011) , 10.1001/ARCHNEUROL.2010.226
Mervyn DI Vergouwen, Marinus Vermeulen, Bert A Coert, Erik SG Stroes, Yvo BWEM Roos, Microthrombosis after aneurysmal subarachnoid hemorrhage : an additional explanation for delayed cerebral ischemia Journal of Cerebral Blood Flow and Metabolism. ,vol. 28, pp. 1761- 1770 ,(2008) , 10.1038/JCBFM.2008.74
Mohammed Sabri, Jinglu Ai, R. Loch Macdonald, Dissociation of Vasospasm and Secondary Effects of Experimental Subarachnoid Hemorrhage by Clazosentan Stroke. ,vol. 42, pp. 1454- 1460 ,(2011) , 10.1161/STROKEAHA.110.604728
R Loch Macdonald, Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage. Expert Opinion on Investigational Drugs. ,vol. 17, pp. 1761- 1767 ,(2008) , 10.1517/13543784.17.11.1761
R Loch Macdonald, Randall T Higashida, Emanuela Keller, Stephan A Mayer, Andy Molyneux, Andreas Raabe, Peter Vajkoczy, Isabel Wanke, Doris Bach, Aline Frey, Angelina Marr, Sébastien Roux, Neal Kassell, Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2) Lancet Neurology. ,vol. 10, pp. 618- 625 ,(2011) , 10.1016/S1474-4422(11)70108-9
C. E. Lovelock, G. J. E. Rinkel, P. M. Rothwell, Time trends in outcome of subarachnoid hemorrhage Population-based study and systematic review Neurology. ,vol. 74, pp. 1494- 1501 ,(2010) , 10.1212/WNL.0B013E3181DD42B3